Cogent Biosciences Inc (NAS:COGT)
$ 9.99 -1.88 (-15.84%) Market Cap: 1.09 Bil Enterprise Value: 1.09 Bil PE Ratio: 0 PB Ratio: 4.22 GF Score: 33/100

Cogent Biosciences Inc To Discuss Lead-In GIST Data at ASCO from the Ongoing PEAK Phase 3 Trial Evaluating Bezuclastinib in Combination with Sunitinib Call Transcript

Jun 05, 2023 / 12:00PM GMT
Release Date Price: $13.24 (+2.08%)
Operator

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to the Cogent Biosciences webcast. (Operator Instructions) Please note that this conference is being recorded.

I will now hand the conference over to your speaker host for today, Christi Waarich, Senior Director of Investor Relations. Please go ahead.

Christi Waarich
Cogent Biosciences, Inc. - Senior Director of IR

Thank you, operator. Today's call will review the positive lead-in data from our ongoing Phase III PEAK trial, evaluating bezuclastinib and sunitinib in patients with GIST. These data were presented in the poster session at ASCO and released in a press release over the weekend. You can find the press release in the Investors & Media section of our website at cogentbio.com.

Before we get started, please be reminded that remarks made during this call may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development time lines,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot